Building a Pre-Made Peptide Vaccine Library for Leukemia Immunotherapy
Researchers designed a pre-built warehouse of tumor-associated peptides for personalized CLL vaccines, bypassing the need for costly individualized vaccine design.
Quick Facts
What This Study Found
The team used mass spectrometry to compare protein fragments displayed on CLL cells versus normal tissue. They found several tumor-associated fragments that appeared often across many CLL patients.
These fragments triggered immune responses from both existing and newly created T cells in CLL patients and healthy volunteers. The researchers packaged these peptides into a pre-made warehouse, so doctors could quickly assemble a personalized multi-peptide vaccine for each patient without starting from scratch.
This matters because CLL has very few mutations, making it hard to find unique cancer targets. The warehouse approach sidesteps this problem by using non-mutated but tumor-associated peptides that still provoke an immune response.
Key Numbers
Clinical trial NCT04688385 launched; T cell responses confirmed in CLL patients and healthy volunteers
How They Did This
Researchers collected CLL samples from patients and compared them to a database of normal tissue samples. They used mass spectrometry to identify protein fragments (immunopeptidome) displayed on cancer cell surfaces. They then tested whether these fragments could activate T cells from both CLL patients and healthy people. A phase I clinical trial (NCT04688385) was launched using the resulting peptide warehouse.
Why This Research Matters
Most peptide cancer vaccines require expensive, time-consuming custom design for each patient. This study shows a way to pre-build a library of peptides that work across many patients. For cancers like CLL that have few mutations, this warehouse model could make peptide vaccines practical and affordable.
The Bigger Picture
Peptide cancer vaccines have long been considered promising but impractical for widespread use due to the need for personalization. This warehouse approach could change that by making it possible to quickly assemble a patient-specific vaccine from pre-validated components. The strategy is especially valuable for cancers with few mutations — like CLL — where finding unique tumor targets has been a major obstacle. If successful in clinical trials, the workflow could be applied to many other cancer types.
What This Study Doesn't Tell Us
This study describes the workflow and initial immune responses but does not yet show whether the vaccines shrink tumors or extend survival. The clinical trial is still in early stages. The immune responses were measured in lab conditions, and real-world vaccine performance may differ. The sample size of CLL patients analyzed for immunopeptidome data was not large.
Questions This Raises
- ?Will the warehouse peptide vaccines produce clinical responses in the ongoing Phase I trial?
- ?How many peptides from the warehouse are needed per patient to generate a robust anti-tumor immune response?
- ?Can this warehouse approach be extended to solid tumors with similarly low mutational burdens?
Trust & Context
- Key Stat:
- Clinical trial NCT04688385 launched The peptide warehouse approach moved from laboratory development directly to a first-in-human clinical trial for chronic lymphocytic leukemia.
- Evidence Grade:
- This is a translational study demonstrating proof-of-concept for a peptide vaccine warehouse approach, with in vitro T cell response data and a clinical trial initiated. Efficacy data from the trial is not yet available.
- Study Age:
- Published in 2021, the associated clinical trial (NCT04688385) may now have early results. The immunopeptidomics workflow remains current and relevant to the growing field of peptide-based cancer immunotherapy.
- Original Title:
- Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.
- Published In:
- Frontiers in immunology, 12, 705974 (2021)
- Authors:
- Nelde, Annika(6), Maringer, Yacine(4), Bilich, Tatjana(3), Salih, Helmut R, Roerden, Malte, Heitmann, Jonas S, Marcu, Ana, Bauer, Jens, Neidert, Marian C, Denzlinger, Claudio, Illerhaus, Gerald, Aulitzky, Walter Erich, Rammensee, Hans-Georg, Walz, Juliane S
- Database ID:
- RPEP-05643
Evidence Hierarchy
Frequently Asked Questions
What is a peptide vaccine warehouse and how does it work?
Instead of designing a completely custom vaccine for each cancer patient — which takes months and costs thousands — researchers pre-identify peptides (protein fragments) commonly found on cancer cells across many patients. These are manufactured in advance and stored in a 'warehouse.' When a patient needs treatment, doctors select the right combination from the warehouse to create a personalized vaccine quickly and affordably.
Why is this approach especially useful for CLL?
Chronic lymphocytic leukemia has very few genetic mutations, which means there are few unique 'neoantigen' targets for the immune system. The warehouse approach works around this limitation by using non-mutated but tumor-associated peptides that are overexpressed or specially displayed on CLL cells compared to normal tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05643APA
Nelde, Annika; Maringer, Yacine; Bilich, Tatjana; Salih, Helmut R; Roerden, Malte; Heitmann, Jonas S; Marcu, Ana; Bauer, Jens; Neidert, Marian C; Denzlinger, Claudio; Illerhaus, Gerald; Aulitzky, Walter Erich; Rammensee, Hans-Georg; Walz, Juliane S. (2021). Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.. Frontiers in immunology, 12, 705974. https://doi.org/10.3389/fimmu.2021.705974
MLA
Nelde, Annika, et al. "Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.." Frontiers in immunology, 2021. https://doi.org/10.3389/fimmu.2021.705974
RethinkPeptides
RethinkPeptides Research Database. "Immunopeptidomics-Guided Warehouse Design for Peptide-Based ..." RPEP-05643. Retrieved from https://rethinkpeptides.com/research/nelde-2021-immunopeptidomicsguided-warehouse-design-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.